Advanced search
Publication Cover
Future Medicinal Chemistry Volume 6, 2014 - Issue 4
Submit an article Journal homepage
871
Views
0
CrossRef citations to date
0
Altmetric
Review

Fentanyl-Related Compounds and Derivatives: Current Status and Future Prospects for Pharmaceutical Applications

Ruben S VardanyanDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ85721, USACorrespondence[email protected]
View further author information
&
Victor J HrubyDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ85721, USAView further author information
Pages 385-412 | Published online: 17 Mar 2014

References

  • Woolf CJ , BorsookD, KoltzenburgM, Mechanism-based classifications of pain and analgesic drug discovery. In: Pain: Current Understanding, Emerging Therapies and Novel Approaches to Drug Discovery. Bountra C, Munglani R, Schmidt WK (Eds). Marcel Dekker, NY, USA, 1–8 (2003).
  • Woodcock J , WitterJ, DionneRA. Stimulating the development of mechanism-based, individualized pain therapies.Nat. Rev. Drug Disc.6(9), 703–710 (2007).
  • Kissin I . The Development of new analgesics over the past 50 years: a lack of real breakthrough drugs.Anesth. Analg.110(3), 780–789 (2010).
  • Grape S , SchugSA, LauerS, SchugBS. Formulations of fentanyl for the management of pain.Drugs70(1), 57–72 (2010).
  • Nelson L . Schwaner R. Transdermal fentanyl: pharmacology and toxicology.J. Med. Toxicol.5(4), 230–241 (2009).
  • Jeal W , BenfieldP. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control.Drugs53(1), 109–138 (1997).
  • Darwish M , MessinaJ. Clinical pharmacology of buccal tablet for the treatment of breakthrough pain.Exp. Rev. Clin. Pharmacol.1(1), 39–47 (2008).
  • Taylor DR . Fentanyl buccal tablet: rapid relief from breakthrough pain.Exp. Opin. Pharmacother.8(17), 3043–3051 (2007).
  • Davis MP . Fentanyl for breakthrough pain: a systematic review.Exp. Rev. Neurotherapeut.11(8), 1197–1216 (2011).
  • Mystakidou K , PanagiotouI, GouliamosA. Fentanyl nasal spray for the treatment of cancer pain.Exp. Opin. Pharmacother.12(10), 1653–1659 (2011).
  • Casy AF , HassanMM, SimmondsB, StaniforthD. Structure–activity relations in analgesics based on 4-anilinopiperidine.J. Pharm. Pharmacol.21(7), 434–440 (1969).
  • Bagley JR , KudzmaLV, LalindeNLet al. Evolution of the 4-anilidopiperidine class of opioid analgesics. Med. Res. Rev. 11(4), 403–436 (1991).
  • Vuckovic S , ProstranM, IvanovicMet al. Fentanyl analogs: structure–activity-relationship study. Curr. Med. Chem. 16(19), 2468–2474 (2009).
  • Yadav P , ChauhanJS, GanesanKet al. Synthetic methodology and structure activity relationship study of N-[1-(2-phenylethyl)-piperidin-4-yl]-propionamides. Pharm. Sinica 1(3), 126–139 (2010).
  • Yaksh TL , NoueihedRY, DurantPAC. Studies of the pharmacology and pathology of intrathecally administered 4-anilinopiperidine analogs and morphine in the rat and cat.Anesthesiol.64(1), 54–66 (1986).
  • Planas E . Fentanyl pharmacological characteristics.Dolor.15(1), 7–12 (2000).
  • Poklis A . Fentanyl: a review for clinical and analytical toxicologist.J. Tox. Clin. Tox.33(5), 439–447 (1995).
  • Andrews CJH , Prys-RobertsC. Fentanyl – a review.Clinics Anaesthesiol.1(1), 97–122 (1983).
  • Mather LE . Clinical pharmacokinetics of fentanyl and its newer derivatives.Clin. Pharmacokinet.8(5), 422–446 (1983).
  • Massey J . Stop the pain: fentanyl is a viable alternative to morphine.JEMS36(8), 54–57 (2011).
  • Pasero C . Fentanyl for acute pain management.J. Perianesth. Nurs.20(4), 279–84 (2005).
  • Peng PW , SandlerAN. A review of the use of fentanyl analgesia in the management of acute pain in adults.Anesthesiol.90(2), 576–599 (1999).
  • Grass JA . Fentanyl: clinical use as postoperative analgesic–epidural/intrathecal route.J. Pain Symptom Manage.7(7), 419–430 (1992).
  • Stanley TH . Fentanyl.J. Pain Symptom Manage.29(5S), S67–S71 (2005).
  • Stanley TH . The history and development of the fentanyl series.J. Pain Symptom Manage.7(3 Suppl.), S3–S7 (1992).
  • Casy AF , ParfittRT. Opioid Analgesics: Chemistry and Receptors. Springer, NY, USA (1986).
  • Lenz GR , EvansSM, WaltersDE, HopfingerAJ. Opiates. Academic Press, MA, USA (1986).
  • Lednicer D . Central Analgetics – Chemistry and Pharmacology of Drugs, A Series of Monographs Vol. 1. Wiley-Interscience, NY, USA (1982).
  • Buschmann H , ChristophT, FriderichsE, MaulC. Analgesics: From Chemistry and Pharmacology to Clinical Application. Wiley-VCH, Weinheim, Germany (2002).
  • DeStevens G . Analgetics – Medicinal Chemistry, A Series of Monographs, Vol. 5. Academic Press, NY, USA (1965).
  • Hellerbach J , SchniderO, BesendorfH, PellmontB. Synthetic Analgesics, Part IIA: Morphinans, Organic Chemistry. Vol. VIII. Pergamon Press, London, UK (1966).
  • Nathan B , EddyNB, MayEL. Synthetic Analgesics, Part IIB: Benzomorphans - International Series of Monographs on Organic Chemistry Vol. 8. Pergamon Press, London, UK (1966).
  • Janssen PAJ . Synthetic Analgesics, Part I: Diphenylpropylamines - International Series of Monographs on Organic Chemistry Vol. 3. Pergamon Press, London, UK (1960).
  • Sawynok J , CowanA. Novel Aspects of Pain Management: Opioids and Beyond. Wiley-Liss, NY, USA (1999).
  • Lemke TH , WilliamsDA, RocheVF, ZitoSW. Foye’s Principles of Medicinal Chemistry. Lippincott Williams and Wilkins, WoltersKluwer Health, PA, USA (2013).
  • Abraham DJ , RotellaDP. Burger’s Medicinal Chemistry and Drug Discovery 7th Edition. John Wiley and Sons, Inc., NJ, USA (2010).
  • Teiggle DJ , TaylorJB. Comprehensive Medicinal Chemistry II. Elsevier Science, London, UK (2006).
  • Thomas G . Fundamentals of Medicinal Chemistry. Wiley-Blackwell, NJ, USA (2003).
  • Vardanyan RS , HrubyVJ. Synthesis of Essential Drugs. Elsevier, Amsterdam, The Netherlands (2006).
  • Block J , BealeJM. Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry 11th Edition. Lippincott Williams and Wilkins, PA, USA (2003).
  • Galemmo RA Jr, Janssens FE, Lewi PJ et al. In Memoriam: Dr Paul AJ Janssen (1926–2003). J. Med. Chem.48(6), 1686 (2005).
  • Black J . A personal perspective on Dr Paul Janssen.J. Med. Chem.48(6), 1687–1688 (2005).
  • Van Gestel S , SchuermansV. Thirty-three years of drug discovery and research with Dr Paul Janssen.Drug Dev. Res.8(1–4), 1–13 (1986).
  • Stanley TH , EganTD, Van Aken H. A tribute to Dr Paul AJ Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology. Anesth. Analgesia106(2), 451–462 (2008).
  • Janssen PAJ , JageneauAH, DemoenPJAet al. Compounds related to Pethidine. I. Mannich bases derived from norpethidine and acetophenones. J. Med. Pharm. Chem. 1, 105–120 (1959).
  • Janssen PAJ , JageneauAHM, DemoenPJAet al. Compounds related to pethidine. II. Mannich bases derived from various esters of 4-carboxy-4-phenylpiperidine and acetophenones. J. Med. Pharm. Chem. 1, 309–317 (1959).
  • Janssen PAJ , JageneauAH, DemoenPJAet al. Compounds related to pethidine. III. Basic ketones derived from norpethidine. J. Med. Pharm. Chem. 2, 271–280 (1960).
  • Wright WB Jr, Brabander HJ, Hardy RA Jr. Synthetic analgesics. III. Basic anilides and carbanilates containing the phenylalkyl moiety. J. Org. Chem.26, 485–490 (1961).
  • Janssen PAJ , GardockiJF: US3141823 (1964).
  • Janssen PAJ : FR M2430 (1964).
  • Janssen PA , NiemegeersCJ, DonyJG. The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawl reflex in rats.Arzneimittelforschung13, 502–507 (1963).
  • Janssen PAJ : US3164600 (1965).
  • Janssen PAJ . The development of new synthetic narcotics. In: Opioids in Anesthesia II. Estafanous FG (Ed.). Butterworth-Heinemann, MA, USA, 37–44 (1983).
  • Van Bever WFM , NiemegeersCJE, SchellekensKHL, JanssenPAJ. N-4-substituted 1-(2-arylethyl)-4-piperidinyl-N-phenylpropanamides, a novel series of extremely potent analgesics with unusually high safety margin. Arzneimittelforschung26(8), 1548–1551 (1976).
  • Gardocki JF , YelnoskyJ. Some of the pharmacologic actions of fentanyl citrate and droperidol.Toxicol. Appl. Pharmacol.6(1), 48–62 (1964).
  • Chrubasik J , WustH, Schulte-MontingJet al. Relative analgesic potency of epidural fentanyl, alfentanil, and morphine in treatment of postoperative pain. Anestheziol. 68(6), 929–933 (1988).
  • Reynolds L , RauckR, WebsterLet al. Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain 110(1–2), 182–188 (2004).
  • Planas E . Fentanyl pharmacological characteristics.Dolor15(1), 7–12 (2000).
  • Barutell C , RiberaMV, MartinezPet al. Fentanyl. Dolor 19(2), 98–104 (2004).
  • Andrews CJH , Prys-RobertsC. Fentanyl – a review.Clin. Anaesthesiol.1(1), 97–122 (1983).
  • Schulz R , WusterM, RubiniP, HerzA. Functional opiate receptors in the guinea-pig ileum: their differentiation by means of selective tolerance development.J. Pharmacol. Exp. Ther.219, 547–550 (1981).
  • Mohamed YH , EssawiMYH, PortoghesePS. Synthesis and evaluation of 1- and 2-substituted fentanyl analogs for opioid activity.J. Med. Chem.26(3), 348–352 (1983).
  • Magnan J , PatersonSJ, TavaniA, KosterlitzW. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.Arch. Pharmacol.319(3), 197–205 (1982).
  • Maguire P , TsaiN, KamalJet al. Pharmacological profiles of fentanyl analogs at µ, δ and κ opiate receptors. Eur. J. Pharmacol. 213(2), 219–225 (1992).
  • Jin WQ , PatersonSJ, KosterlitzHW, CasyAF. Interactions of some 4-anilino-piperidines and 4-phenylpiperidines with the µ-, δ- and κ-binding sites.Life Sci.33(Suppl. 1), 251–253 (1983).
  • Boas RA , VilligerJW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.Brit. J. Anaesth.57(2), 192–196 (1985).
  • Lehmann KA , WeskiC, HungerL. Biotransformation of fentanyl. II. Acute drug interactions in rats and men.Anaesthesist31(5), 221–227 (1982).
  • Lehmann KA , HungerL, BrandtK, DaubD. Biotransformation of fentanyl. III. Effect of chronic drug administration on distribution, metabolism and excretion in the rat.Anaesthesist32(4), 165–173 (1983).
  • Jonczyk A , JawdosiukM, MakoszaM, CzyzewskiJ. Search for a new method for synthesis of the analgesic agent “Fentanyl”.Przeml. Chem.57(3), 131–134 (1978).
  • Zee S -H, Wang W-K. A new process for the synthesis of fentanyl. J. Chin. Chem. Soc.27(4), 147–149 (1980).
  • Casy AF , HassanMMA. Analgesically active basic anilides: stereospecificity and structure of the basic group.J. Pharm. Pharmacol.19(1), 17–24 (1967).
  • Wright WB Jr, Hardy RA Jr. Synthetic analgesics. IV. Synthesis of enantiomers of basic anilides containing the phenalkyl moiety. J. Med. Chem.6, 128–130 (1963).
  • Ivanovic MD , MicovicIV, VuckovicSet al. The synthesis and pharmacological evaluation of (±)-2,3-seco-fentanyl analogs. J. Serb. Chem. Soc. 69(11), 955–968 (2004).
  • Helsley GC , LunsfordCD, WelsteadWJ Jr et al. Synthesis and analgetic activity of some 1-substituted 3-pyrrolidinylanilides and dihydrobenz-oxazinones. J. Med. Chem.12(4), 583–586 (1969).
  • Finney ZG , RileyTN. 4-Anilidopiperidine analgesics. 3. 1-Substituted 4-(propananilido)-perhydroazepines as ring-expanded analogs.J. Med. Chem.23(8), 895–899 (1980).
  • DeRuiter J , AndurkarS, RileyTNet al. Investigation of the synthesis and analgesic activity of 1-substituted 4-(propananilido)perhydroazepines. J. Het. Chem. 29(4), 779–786 (1992).
  • Bagley JR , RileyTN. Synthesis and conformational analysis of isomeric 3-propan-anilidotropanes.J. Het. Chem.14(4), 599–602 (1977).
  • Riley TN , BagleyJR. 4-Anilidopiperidine analgesics. 2. A study of the conformational aspects of the analgesic activity of the 4-anilidopiperidines utilizing isomeric N-substituted 3-(propananilido)nor-tropane analogs.J. Med. Chem.22(10), 1167–1171 (1979).
  • Fernandez MJ , HuertasRM, GalvezEet al. Synthesis, and structural, conformational and pharmacological studies of new fentanyl derivatives of the norgranatane system. J. Chem. Soc. Perkin Trans. 2 4, 687–695 (1992).
  • Law S -J, Lewis DH, Borne RF. Synthesis and stereochemical analysis of isomeric N-substituted 5- and 6-propanilido-2-azabicyclo[2.2.2]octanes. J. Het. Chem.15(2), 273–280 (1978).
  • Borne RF , Law S-J, Kapeghian JC, Masten LW. Evaluation of 2-azabicyclo[2.2.2]octane analogs of 4-anilidopiperidine analgesics. J. Pharm. Sci.69(9), 1104–1106 (1980).
  • Riley TN , HaleDB, WilsonMC. 4-Anilidopiperidine analgesics. I. Synthesis and analgesic activity of certain ring-methylated, 1-substituted 4-propananilidopiperidines.J. Pharmaceut. Sci.62(6), 983–986 (1973).
  • Riley TN , HaleDB: US3923992 (1975).
  • Vartanyan SA , VartanyanRS, ZhamagortsyanVNet al. SU736583 (1985).
  • Vartanian RS , AirapetyanGK, MarkaryanEAet al. SU1100848 (1984).
  • Vartanyan RS , MartirosyanVO, VartanyanSAet al. Synthesis and analgesic activity of 4-anilides of 1-substituted 2,5-dimethylpiperidines. Khim. Farm. Zh. 23(5), 562–565 (1989).
  • Karapetyan AA , Struchkov YuT, Timofeeva TV et al. Structure and activity of phenaridine stereoisomers. Khim. Farm. Zh.23(5), 565–572 (1989).
  • Vartanyan RS , MartirosyanVO, VartanyanSAet al. Stereochemistry and biological properties of the new narcotic analgesic phenaridine. Khim. Farm. Zh. 23(5), 573–578 (1989).
  • Van Bever WFM , NiemegeersCJE, JanssenPAJ. Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenyl-propanamide and N-[3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl]-N-phenyl-propanamide. J. Med. Chem.17(10), 1047–1051 (1974).
  • Ivanovic MD , MicovicIV, VuckovicSet al. The synthesis and preliminary pharmacological evaluation of the racemic cis and trans 3-alkylfentanyl analogs. J. Serb. Chem. Soc. 69(7), 511–526 (2004).
  • Karapetyan HA , Struchkov YuT, MartirosyanVOet al. The structure of analgesics of the 4-anilinopiperidine series. III. Structure of 1(e)-(2-phenethyl)-2(e),5(e)-dimethyl-4(e)-(N-propionylanilino)piperidine bisulfate. Zh. Strukt. Kh.31(2), 141–145 (1990).
  • Karapetyan AA , TimofeyevaTV, Struchkov YuT, Martirosyan VO. Conformation of the 4-(propionylanilino) pharmacophore in stereoisomers of the 2,5-dimethyl derivative of phentanyl (phenaridine). Khim. Farm. Zh.26(9–10), 25–28 (1992).
  • Dzhingozyan VK , MartirosyanVO, KarapetyanAAet al. Effect of 2-methyl substituent on the conformation of 1-(2-phenylethyl) pharmacophore in 4-propanoyl(phenyl)piperidines. Khim. Farm. Zh. 30(8), 40–42 (1996).
  • Lalinde NL , MoliterniJ, SpencerHK: US4939161 (1990).
  • Prost M : DE2656678 (1977).
  • Micovic IV , IvanovicMD, VuckovicSMet al. The synthesis and preliminary pharmacological evaluation of 4-methyl fentanyl. Bioorg. Med Chem. Lett. 10(17), 2011–2014 (2000).
  • Kudzma LV , SevernakSA, BenvengaMJet al. 4-phenyl- and 4-heteroaryl-4-anilido-piperidines. A novel class of analgesic and anesthetic agents. J. Med. Chem. 32(12), 2534–2542 (1989).
  • Lin B -S, Kudzma LV, Spencer HK: US4791120 (1988).
  • Kudzma LV , SpencerHK: US4801615 (1989).
  • Van Daele PG , De BruynMF, BoeyJMet al. Synthetic analgesics: N-(1-[2-arylethyl]-4-substituted 4-piperidinyl) N-arylalkanamides. Arzneimittelforschung26(8), 1521–31 (1976).
  • Janssen PAJ , Van Daele GHP: US4179569 (1979).
  • Thompson RG , Menking,D, ValdesJJ. Opiate receptor binding properties of carfentanil.Chem. Res. Dev. Eng. Cent. Report (1987).
  • Van Bever WFM , NiemegeersCJE, SchellekensKHL, JanssenPAJ. N-4-substituted 1-(2-arylethyl)-4-piperidinyl-N-phenylpropanamides, a novel series of extremely potent analgesics with unusually high safety margin. Arzneimittelforschung26(8), 1548–1551 (1976).
  • Niemegeers CJ , SchellekensKH, Van Bever WF, Janssen PA. Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs. Arzneimittelforschung26(8), 1551–1556 (1976).
  • Janssens F , TorremansJ, JanssenPAJ. Synthetic 1,4-disubstituted 1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.J. Med. Chem.29(11), 2290–2297 (1986).
  • Niemegeers CJE , JanssenPAJ. Alfentanil (R 39 209) – a particularly short-acting intravenous narcotic analgesic in rats.Drug Dev. Res.1(1), 83–88 (1981).
  • Bagley JR , ThomasSA, RudoFGet al. New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics. J. Med. Chem. 34(2), 827–841 (1991).
  • Janssen PAJ ,Van Daele GHP: US4179569 (1979).
  • Kiricojevic VD , IvanovicMD, MicovicIVet al. An optimized synthesis of a key pharmaceutical intermediate: methyl 4-[(1-oxopropyl) phenylamino]piperidine-4-carboxylate. J. Serb. Chem. Soc. 67(12), 793–802 (2002).
  • Srimurugan S , MuruganK, ChenC. A facile method for preparation of [2H3]-sufentanil and its metabolites. Chem. Pharm. Bull.57(12), 1421–1424 (2009).
  • Henriksen G , PlatzerS, MartonJet al. Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as µ-opioid receptor imaging agents. J. Med. Chem. 48(24), 7720–7732 (2005).
  • Feldman PL , JamesMK, BrackeenMFet al. Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgesics. J. Med. Chem. 34(7), 2202–2206 (1991).
  • Feldman PL , JamesMK, BrackeenMF, JohnsonMR, LeightonH: EP383.579 (1990).
  • Cui Y , PanL, NingY, ZhangK, ZhengJ. Analgesic effect and time-effect relation of remifentanil.Zhongguo Yaowu Yilaixing Zazhi12(4), 268–269, 283 (2003).
  • Nora FS , FortisE, AparecidaF. Remifentanil: do we need another opioid?Rev. Bras. Anestesiol.51(2), 146–159 (2001).
  • Battershill AJ , KeatingGM. Remifentanil: a review of its analgesic and sedative use in the intensive care unit.Drugs66(3), 365–385 (2006).
  • Scott LJ , PerryCM. Remifentanil. A review of its use during the induction and maintenance of general anaesthesia.Drugs65(13), 1793–1823 (2005).
  • Beers R , CamporesiE. Remifentanil update: clinical science and utility.CNS Drugs52(6), 1095–1104 (2004).
  • Wilhelm W , WrobelM, KreuerS, LarsenR. Remifentanil. An update,Anaesthesist52(6), 473–494 (2003).
  • Rosow CE . An overview of remifentanil.Anesth. Analg.89(4 Suppl.), S1–S3 (1999).
  • Peacock JE . Remifentanil clinical studies.Drugs Today33(9), 619–626 (1997).
  • Patel SS , SpencerCM. Remifentanil.Drugs52(3), 417–427 (1996).
  • Buerkle HDS , Van Aken H. Remifentanil: a novel, short-acting, µ-opioid. Anesth. Analg.83(3), 646–651 (1996).
  • James MK . Remifentanil and anesthesia for the future.Exp. Opin. Invest. Drugs3(4), 331–340 (1994).
  • Floegel O , WeiglU: WO2010000282 (2010).
  • Cheng BK -M, Halvachs RE: WO2008066708 (2008).
  • Cheng B : WO2008045192 (2008).
  • Jacob M , KillgoreJK: WO2001040184 (2001).
  • Malaquin S , Jida,M, Gesquiere J-C et al. Ugi reaction for the synthesis of 4-aminopiperidine-4-carboxylic acid derivatives. Application to the synthesis of carfentanil and remifentanil. Tetr. Lett.51(22), 2983–2985 (2010).
  • Colapret JA , DiamantidisG, SpencerHKet al. Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines. J. Med. Chem. 32(5), 968–974 (1989).
  • Casy AF , HuckstepMR. Structure-activity studies of fentanyl.J. Pharm. Pharmacol.40(9), 605–608 (1988).
  • Peters D , EriksenBL, MunroGN, OestergaardE: WO2009077584 (2009).
  • Bagley JR , WynnRL, RudoFGet al. New 4-(heteroanilido)piperidines, structurally related to the pure opioid agonist fentanyl, with agonist and/or antagonist properties. J. Med. Chem. 32, 663–671 (1989).
  • Wynn RL , BagleyJR, SpencerHK, SpauldingTC. Evaluation of the morphine reversal actions and antinociceptive activity of a new class of opiate antagonists structurally related to fentanyl.Drug Develop. Res.22(2), 189–195 (1991).
  • Vartanian RS , VartanianSA, MartirosyanVOet al. SU1139125 (1984).
  • Jagerovic N , CanoC, ElgueroJet al. Long-acting fentanyl analogs: synthesis and pharmacology of N-(1-phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. Bioorg. Med. Chem. 10(3), 817–827 (2002).
  • Giron R , AbaloR, GoicoecheaCet al. Synthesis and opioid activity of new fentanyl analogs. Life Sci. 71(9), 1023–3104 (2002).
  • Jimeno ML , AlkortaI, CanoCet al. Fentanyl and its analog N-(1-phenylpyrazol-3-yl)-N-[1-(2-phenylethyl)-4-piperidyl]propanamide: 1H- and 13C-NMR spectroscopy, x-ray crystallography, and theoretical calculations. Chem. Pharm. Bull. 51(8), 929–934 (2003).
  • Goicoechea C , SanchezE,Cano C et al. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally. Eur. J. Pharmacol.595(1–3), 22–29 (2008).
  • Montero A , GoyaP, JagerovicNet al. Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for µ opioid and I2-imidazoline receptors: synthesis and pharmacological screening. Bioorg. Med. Chem. 10(4), 1009–1018 (2002).
  • Dardonville C , JagerovicN, CalladoLF, MeanaJJ. Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites. Bioorg. Med. Chem. Lett.14(2), 491–493 (2004).
  • Lalinde NL , MoliterniJ, SpencerHK: US4994471 (1991).
  • Micovic IV , IvanovicMD, VuckovicSet al. 3-Carbomethoxy fentanyl: synthesis, pharmacology and conformational analysis. Het. Comm. 4(2), 171–179 (1998).
  • Vuckovic S , ProstranM, IvanovicMet al. Antinociceptive activity of novel fentanyl analog iso-carfentanyl in rats. Jpn. J. Pharmacol. 84, 188–195 (2000).
  • Essawi MYH , PortoghesePS. Synthesis and evaluation of 1- and 2-substituted fentanyl analogs for opioid activity.J. Med. Chem.26(3), 348–352 (1983).
  • Micovic IV , RoglicGM, IvanovicMDet al. The synthesis of lactam analogs of fentanyl. J. Chem. Soc. Perkin Trans. 1(16), 2041–2050 (1996).
  • Micovic IV , RoglicGM, IvanovicMDet al. The synthesis of 3,3-dimethylfentanyl and its lactam analog. J. Serb. Chem. Soc. 61(10), 849–857 (1996).
  • Klein W , BackW, MutschlerE. Potential analgesics. 3. 1-(4-piperidinyl)-2-indolinones and -3,4-dihydrocarbostyrils.Arch. Pharm.307(5), 360–366 (1974).
  • Walker GN , SmithRT, WeaverBN. Synthesis of new 3-(pyridylmethylene)-, 3-(pyridylmethyl)-, 3-(piperidylmethyl)-, and 3-(β-alkylaminoethyl)-2-indolinones. The reduction of isoindogenides, nitro compounds, and pyridines in a series of 2-indolinones.J. Med. Chem.8(5), 626–637 (1965).
  • Lobbezoo MW , SoudijnW, Van Wijngaarden I. Opiate receptor interaction of compounds derived from or structurally related to fentanyl. J. Med. Chem.24(7), 777–782 (1981).
  • Vartanyan RS , MartirosyanVO, VlasenkoEV, OvasapyanAA. Synthesis and biological activity of 1-substituted benzimidazole and benztriazole derivatives.Khim. Farm. Zh.16(8), 947–951 (1982).
  • Kudzma LV , EvansSM, TurnbullSPet al. Octahydro-1,2,3,4,4a,5,11,11a-pyrido3,4-c1,5benzoxazepines conformationally restricted fentanyl analogs. Bioorg. Med. Chem. Lett. 5(11), 1177–1182 (1995).
  • Van Dyke JW Jr, Havera HJ, Johnson RD et al. Cardiovascular activity of some substituted 2-aminobenzoquinolizines. J. Med. Chem.15(1), 91–94 (1972).
  • Maryanoff BE , McComseyDF, TaylorRJet al. Synthesis and stereochemistry of 7-phenyl-2-propionanilidobenzo[a]quinolizidine derivatives. Structural probes of fentanyl analgesics. J. Med. Chem. 24(1), 79–88 (1981).
  • Vardanyan R , VijayG, NicholGSet al. Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg. Med. Chem. 17(14), 5044–5053 (2009).
  • Tollenaere JP , MoereelsH, RaymaekersLA. Atlas of the Three-Dimensional Structure of Drugs, Vol. 1. Elsevier/North-Holland Inc., Amsterdam, The Netherlands (1979).
  • Koch MHJ , de Ranter CJ, Rolies M, Dideberg O. N-[4-(methoxymethyl)-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide. Acta Crystallogr. Sect. B32, 2529–2531 (1976).
  • Spickett W . Compounds affecting the central nervous system. II. Substituted 1,2,3,4-tetrahydropyrido [4,3-b] indoles.J. Med. Chem.9(3), 436–438 (1966).
  • Berger JG , DavidsonF, LangfordGE. Synthesis of some conformationally restricted analogs of fentanyl.J. Med. Chem.20(4), 600–602 (1977).
  • Wang Z -X, Zhu Y-C, Jin W-Q et al. Stereoisomers of N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]N-phenylpropanamide: synthesis, stereochemistry, analgesic activity, and opioid receptor binding characteristic. J. Med. Chem.38(18), 3652–3659 (1995).
  • Brine GA , StarkPA, LiuJYet al. Enantiomers of diastereomeric cis-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamides: synthesis, x-ray analysis, and biological activities. J. Med. Chem. 38(9), 1547–1557 (1995).
  • Rice KC , JacobsonAE, BurkeTR Jr et al. Irreversible ligands with high selectivity toward δ or µ opiate receptors. Science220(4594), 314–316 (1983).
  • Burke TR Jr, Bajwa BS, Jacobson AE et al. Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for µ or δ opiate receptors. J. Med. Chem.27(12), 1570–1574 (1984).
  • Burke TR Jr, Jacobson AE, Rice KC et al. Probes for narcotic receptor mediated phenomena. 12. cis>-(+)-3-methyl-fentanyl isothiocyanate, a potent site-directed acylating agent for δ opioid receptors. Synthesis, absolute configuration, and receptor enantioselectivity. J. Med. Chem.29(6), 1087–1093 (1986).
  • Chen B -Y, Jin W-Q, Chen Jie et al. Analgesic activity and selectivity of isothiocyanate derivatives of fentanyl analogs for opioid receptor. Life Sci.65(15), 1589–1595 (1999).
  • Dardonville C , Fernandez-FernandezG, Gibbons S-L et al. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the µ-opioid receptor and I2–imidazoline binding sites. Bioorg. Med. Chem.14(19), 6570–6580 (2006).
  • Weltrowska G , ChungNN, LemieuxCet al. “Carba”-analogs of fentanyl are opioid receptor agonists. J. Med. Chem. 53(7), 2875–2881 (2010).
  • Srulevitch DB , LienEJ. 4-phenylamidopiperidines: synthesis, pharmacological testing and SAR analysis.Acta Pharm. Jugoslavica41(2), 89–106 (1991).
  • Gupta PK , YadavSK, BhutiaYDet al. Synthesis and comparative bioefficacy of N-(1-phenethyl-4-piperidinyl)propionanilide (fentanyl) and its 1-substituted analogs in Swiss albino mice. Med. Chem. Res. 22(8), 3888–3896 (2013).
  • Vartanyan RS , Gyul‘budagyanAL, KhanamiryanA Kh et al. Synthesis of 1-phenethyl-2-methyl- and 1-methyl-2-phenethyl-4-(N-propionylanilino)hexahydro pyridazines. Arm. Khim. Zh.40(9), 563–569 (1987).
  • Jilek J , RajsnerM, ValentaVet al. Synthesis of piperidine derivatives as potential analgesic agents. Coll. Czech. Chem. Comm. 55(7), 1828–1853 (1990).
  • Morphy R , RankovicZ. Designed multiple ligands, an emerging drug discovery paradigm.J. Med. Chem.48(21), 6523–6543 (2005).
  • Dietis N , GuerriniR, SalvadoriCGet al. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br. J. Anaesth. 103(1), 38–49 (2009).
  • Liu Z , ZhangJ, ZhangA. Design of multivalent ligand targeting G-protein-coupled receptors.Curr. Pharm. Des.15(6), 682–718 (2009).
  • Schiller PW . Bi- or multifunctional opioid peptide drugs.Life Sci.86, 598–603 (2010).
  • Shonberg J , ScammellsPJ, CapuanoB. design strategies for bivalent ligands targeting GPCRs.ChemMedChem6, 963–974 (2011).
  • Balboni G , SalvadoriS, MarczakEDet al. Opioid biunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. Eur. J. Med. Chem. 46(2), 799–803 (2011).
  • Hruby VJ , PorrecaF, YamamuraHIet al. New paradigms and tools in drug design for pain and addiction. AAPS J. 8(3), E450–E460 (2006).
  • Kumirov R , VK, Nichol GS et al. Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands. Bioorg. Med. Chem.19(20), 6135–6142 (2011).
  • Petrov RR , VardanyanRS, LeeYSet al. Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogs for opioid activity. Bioorg. Med. Chem. Lett. 16(18), 4946–4950 (2006).
  • Nichol GS , VardanyanR, HrubyVJ. Synthesis and crystallographic study of N´-(1-benzylpiperidin-4-yl)acetohydrazide.J. Chem. Crystallography40(11), 961–964 (2010).
  • Vardanyan R , KumirovVK, HrubyVJ. Improved synthesis of d,l-fluoro-citric acid.J. Fluorine Chem.132(11), 920–924 (2011).
  • Porreca F , TakemoriAE, SultanaMet al. Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J. Pharm. Exp. Therapeut. 263(1), 147–152 (1992).
  • Heyman JS , VaughtJL, MosbergHIet al. Modulation of mu-mediated antinociception by delta agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen2,D-Pen5]enkephalin. Eur. J. Pharm. 165(1), 1–10 (1989).
  • Heyman JS , JangQ, RothmanRBet al. Modulation of µ-mediated antinociception by delta agonists: characterization with antagonists. Eur. J. Pharm. 169(1), 43–52 (1989).
  • Schiller PW , FundytusME, MerovitzLet al. The opioid µ agonist/δ antagonist DIPP-NH2[ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J. Med. Chem. 42(18), 3520–3526 (1999).
  • Rozenfeld R , DeviLA. Receptor heterodimerization leads to a switch in signaling: β-arrestin2-mediated ERK activation by µ-δ opioid receptor heterodimers.FASEB J.21(10), 2455–2465 (2007).
  • Gomes I , GuptaA, FilipovskaJet al. A role for heterodimerization of µ and δ opiate receptors in enhancing morphine analgesia. Proc. Natl Acad. Sci. USA 101(14), 5135–39 (2004).
  • Scherrer G , ImamachiN, Cao Y-Q et al. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell137(6), 1148–59 (2009).
  • Horan PJ , MattiaA, BilskyEJet al. Antinociceptive profile of biphalin, a dimeric enkephalin analog. J. Pharm. Exp. Ther. 265(3), 1446–1454 (1993).
  • Lee YS , NybergJ, MoyeSet al. Understanding the structural requirements of 4-anilidopiperidine analogs for biological activities at µ and δ opioid receptors. Bioorg. Med. Chem. Lett. 17(8), 2161–2165 (2007).
  • Lee YS , PetrovR, KulkarniVet al. Development of µ/δ opioid ligands: enkephalin analogs containing 4-anilidopiperidine moiety. Adv. Exp. Med. Biol. 611, 517–518 (2009).
  • Lee YS , PetrovR, ParkCKet al. Development of novel enkephalin analogs that have enhanced opioid activities at both µ and δ opioid receptors. J. Med. Chem. 50(22), 5528–5532 (2007).
  • Lee YS , KulkaraniV, CowellSMet al. Development of potent µ and δ opioid agonists with high lipophilicity. J. Med. Chem. 54(1), 382–386 (2011).
  • Xu X , KimCH, ZhuYCet al. (+)-cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: evidence for pseudoallosteric modulation. Neuropharmacology 30(5), 455–62 (1991).
  • Jin WQ , XuH, ZhuYCet al. Studies on synthesis and relationship between analgesic activity and receptor affinity for 3-methyl fentanyl derivatives. Sci. Sin. 24, 710–720 (1981).
  • Maguire P , TsaiN, KamalJet al. Pharmacological profiles of fentanyl analogs at µ, δ and κ opiate receptors. Eur. J. Pharmacol. 213(2), 219–225 (1992).
  • Tollenaere JP , MoereelsH, van Loon M. On conformation analysis, molecular graphics, fentanyl and its derivatives. Prog. Drug Res.30, 91–126 (1986).
  • Martins J , AndrewsP. Conformation-activity relationships of opiate analgesics.J. Comput. Aided Mol. Des.1, 53–72 (1987).
  • Cometta-Morini C , LoewGH. Development of a conformational search strategy for flexible ligands: a study of the potent m-selective opioid analgesic fentanyl.J. Comput. Aided Mol. Des.5, 335–356 (1991).
  • Cometta-Morini C , MaguirePA, LoewGH. Molecular determinants of í receptor recognition for the fentanyl class of compounds.Mol. Pharmacol.41, 185–196 (1992).
  • Brandt W , BarthA, Holtje H-D. A new consistent model explaining structure (conformation)-activity relationships of opiates with í-selectivity. Drug Des. Discov.10, 257–283 (1993).
  • Rong S -B, Zhu Y-C, Jiang H-L et al. Interaction models of 3-methylfentanyl derivatives with mu opioid receptors. Acta Pharmacol. Sin.18, 128–132 (1997).
  • Subramanian GM , PaterliniG, PortoghesePSet al. Molecular docking reveals a novel binding site model for fentanyl at the µ-opioid receptor. J. Med. Chem. 43(3), 381–391 (2000).
  • Dosen-Micovic L , IvanovicM, MicovicV. Steric interactions and the activity of fentanyl analogs at the µ-opioid receptor.Bioorg. Med. Chem.14(9), 2887–2895 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.